Gilead Sciences Inc - GILD STOCK NEWS

Gilead Sciences (GILD) announced new data from its HIV and COVID-19 research programs, to be presented at CROI 2022 from February 12-16. Findings highlight the role of Veklury (remdesivir) in treating COVID-19 and showcase advancements in HIV treatment, including one-year results from the CALIBRATE and CAPELLA trials on lenacapavir. Gilead affirms its commitment to addressing unmet health needs through innovative research, especially amidst ongoing global health challenges.

Gilead Sciences (NASDAQ: GILD) announced its participation in three upcoming investor conferences. Executives will present at:

• SVB Leerink Annual Global Healthcare Conference on February 16 at 2:20 PM ET
• Raymond James Annual Institutional Investors Conference on March 8 at 1:05 PM ET
• Cowen Annual Health Care Conference on March 9 at 10:30 AM ET

Live webcasts will be available on the company’s investors page with replays accessible for at least 30 days.

Gilead Sciences has declared a 2.8% increase in its quarterly cash dividend, raising it to $0.73 per share. The new dividend will take effect in the first quarter of 2022.

Shareholders of record by March 15, 2022 will receive the dividend on March 30, 2022. Future dividends are subject to Board approval, reflecting Gilead’s ongoing commitment to rewarding its investors.

Gilead Sciences reported a 2% decrease in fourth quarter 2021 revenue to $7.2 billion, impacted by lower Veklury sales, despite a 19% year-over-year increase in Biktarvy sales. The diluted EPS fell to $0.30 due to a $1.25 billion legal settlement charge and a $625 million Arcus opt-in charge. Full-year 2021 revenue rose to $27.3 billion, with EPS increasing to $4.93, helped by Veklury's 98% growth. R&D expenses rose to $5.4 billion, reflecting ongoing clinical commitments. 2022 guidance anticipates product sales of $23.8-$24.3 billion and EPS between $4.70 and $5.20.

FDA Approves Update for Yescarta: Gilead's Kite has received FDA approval for an update to the prescribing information of Yescarta (axicabtagene ciloleucel). This update allows for the use of prophylactic corticosteroids across all approved indications, marking Yescarta as the first CAR T-cell therapy with guidelines for managing treatment-related side effects. The update is based on a safety management cohort from the ZUMA-1 study, showing a significant reduction in severe cytokine release syndrome (CRS) events compared to prior cohorts.

Gilead Sciences (Nasdaq: GILD) has announced a partial clinical hold on studies evaluating the combination of magrolimab and azacitidine due to suspected unexpected serious adverse reactions (SUSARs). This hold will pause new patient enrollment in the affected studies while current participants can continue receiving treatment. Other magrolimab studies remain unaffected. Gilead is collaborating with regulatory authorities to determine next steps and emphasizes patient safety as a priority.

Gilead Sciences announced the FDA's expedited approval of Veklury (remdesivir) for non-hospitalized adults and adolescents at high risk of severe COVID-19. The approval allows outpatient administration over three days and expands the pediatric EUA to include children under 12. Veklury showed an 87% reduction in hospitalization risk in clinical trials. This development comes amid rising COVID-19 cases and variants' impact on treatment options.

Gilead is committed to ensuring availability in outpatient settings while maintaining supply for hospitalized patients.

Gilead Sciences, Inc. (NASDAQ: GILD) announced that it will release its fourth quarter and full year 2021 financial results on February 1, after market close. Management will discuss these results in a live webcast at 4:30 PM ET on the same day. Investors can access the webcast through Gilead's investor relations page and it will be archived for one year. Gilead has been a leader in biopharmaceuticals for over three decades, focusing on innovative treatments for serious diseases such as HIV, hepatitis, and cancer.

Gilead Sciences (NASDAQ: GILD) announced collaborations with Merck to evaluate Trodelvy in combination with KEYTRUDA for first-line treatment of metastatic non-small cell lung cancer (NSCLC). Merck will sponsor a global Phase 3 trial, while Gilead will conduct a Phase 2 study. NSCLC, as the leading lung cancer type, presents a significant unmet medical need due to a low five-year survival rate of 25%. Trodelvy, currently approved for certain cancers, is under investigation for this new indication, and the safety and efficacy for NSCLC treatment remain unestablished.